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ABSTRACT
AlgR Directly Controls rsmA in Pseudomonas aeruginosa
by
Tyler Speaks
Pseudomonas aeruginosa is a bacterial pathogen that can infect any human tissue. The lungs of
cystic fibrosis patients become chronically infected with Pseudomonas aeruginosa. Virulence
factor gene expression is under elaborate regulatory control that remains poorly characterized.
Understanding the regulatory hierarchy involved during infection is essential for identifying
novel drug targets. RsmA is a post-transcriptional regulatory protein that controls expression of
several virulence factors. Previous studies demonstrated alginate regulatory components AlgU
and AlgR as regulators of rsmA expression. The aim of this study was to determine how AlgR
controls rsmA expression. Western blot analysis of HA-tagged RsmA confirmed lower RsmA
levels in an algR mutant. An electrophoretic mobility shift assay using purified AlgR
demonstrated direct binding of AlgR to the rsmA promoter. These results indicate AlgR directly
controls rsmA expression. We propose a mechanism whereby AlgR and AlgU work together to
regulate rsmA.
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CHAPTER 1
INTRODUCTION
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a Gram negative, opportunistic pathogen capable of
surviving in a diverse array of environmental and host reservoirs. P. aeruginosa exploits a
compromised host immune system to cause opportunistic infections, and is able to infect any
tissue within the human body (3, 42). P. aeruginosa commonly causes nosocomial infections
and is a major agent of sepsis in burn patients, eye infections, urinary tract infections, ventilator
associated pneumonia and fatal infection in lungs of cystic fibrosis patients (3, 29, 42). P.
aeruginosa is able to infect such diverse tissues because of a wide array of virulence factors
under elaborate genetic control (26, 62). The pathogen’s ability to persist in a biofilm is also a
major virulence determinant that results in immune evasion and persistence (13, 29, 39). P.
aeruginosa infects cystic fibrosis patients at an early age and eventually sets up a chronic
infection that becomes the leading cause of mortality for these patients (23).
Pseudomonas aeruginosa Infection in Cystic Fibrosis Patients
Cystic fibrosis (CF) is the most commonly inherited lethal disorder among Caucasians,
occurring in roughly 1 per 2,500 individuals (10). The disorder results from a loss of function
mutation in CFTR, which encodes an ion channel transfer protein (20). Individuals possess lungs
with sticky mucus and diminished mucociliary clearing capacity. The patient’s diminished
respiratory innate defense results in colonization and infection with a variety of bacteria (8). In
previous years, patients succumbed at an early age to infections from Staphylococcus aureus and
Haemophilus influenzae. With the advent of new antibiotic therapies came the infiltration and
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dominance of new infecting strains, with Pseudomonas aeruginosa emerging as the deadliest
pathogen (11, 23). Patients become colonized with P. aeruginosa from the environment at an
early age, and the lungs become subject to repeat acute infections, causing inflammation related
lung damage (8, 23, 29). Clinical isolates from acute lung infections resemble strains found
infecting other areas of the body (4, 66). Isolates are typically motile, by mechanisms involving
flagellar swimming, twitching by Type IV pili, swarming as a combination of both, and finally
gliding motility enabled by production of biosurfactants (4, 5, 9, 53). Acute infecting strains also
possess a Type III secretion system that targets toxins to human cells, resulting in damage to host
cell machinery and cell death (60). P. aeruginosa is also capable of producing other secreted
toxins, proteases, elastases and hemolysins to damage the host (50, 54). Though biofilms are a
hallmark of chronic infecting strains, acute strains are also capable of such a lifestyle. Biofilms
are regulated by the pel and psl genes, which produce a different polysaccharide than the alginate
typical of chronic isolates (53, 58). During the course of acute infection, repeated stress to the
bacteria within the lungs results from antibiotics, immune reactive oxygen species, and
osmotic/cell membrane stress. These stressors place selective pressure on the virulent bacteria
that eventually lead to the emergence and prevalence of sessile, chronic infecting strains (29, 41,
61). Chronic infecting strains possess different genetic and phenotypic markers from their acute
counterparts, and can often be designated by attenuated virulence and heavy alginate biofilms
(13, 29, 66). Commonly, chronic isolates overproduce the exopolysaccharide alginate, resulting
in the mucoid colony morphology (13, 29, 65 and Figure 1). The conversion to mucoidy is
associated with declining lung function and poor prognosis for the patient (23, 29). The alginate
produced by mucoid strains protects P. aeruginosa from phagocytic pseudopods, opsonin
deposition on the cell surface, and free radicals produced by immune cells (29, 30, 57). A
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damaging feedback loop results within the lung, where neutrophils are unable to clear the
bacteria but continually secrete inflammatory cytokines for further phagocyte recruitment. This
inflammation, along with damage caused by the bacteria, leads to severe lung damage and
eventual death to the patient from loss of lung function (23, 29, 57). This serious pathology has
resulted in a large amount of study over the last several decades in elucidating the means by
which P. aeruginosa converts to a mucoid strain.
Mucoid Phenotype and Alginate Regulation
Mucoid clinical isolates differ from acute infecting strains as a result of genetic mutations
that lead to production of different virulence factors (66). To fully understand the reasons for
this, it is necessary to review the main regulatory system involved in conversion to a mucoid
strain. At the center of this switch are the products of the algUmucABCD operon, which
illustrate a system involved in responding to stresses on the cell membrane (36, 40).
In a typical acute infecting strain, the MucA anti-sigma factor bound within the
cytoplasmic membrane sequesters the sigma factor AlgU, also known as AlgT or σ22 (40, 51,
66). AlgU bears homology to E. coli σE, a membrane stress response sigma factor (1, 29). AlgU
controls a large regulon of genes involved in osmotic stress responses, metabolite production and
alginate biosynthesis (22, 56). Activation of this regulon by the normally bound AlgU can occur
in two ways. First, membrane or oxidative stress can result in direct or proteolytic degradation
of MucA, which releases AlgU. AlgU then increases its own expression and controls expression
of genes to combat the environmental stresses (29, 40, 56). In the CF lung, the bacteria are
subject to hypermutation that results in a wide variety of phenotypic variants to increase
survivability (17). Mutations in DNA mismatch repair systems can lead to mucA loss of function
mutations (41). In addition, peroxide stress has been shown to increase the recruitment of DinB,
10

an error-prone Pseudomonas DNA polymerase (59). The mucoid phenotype eventually emerges
through a chromosomal mutation in mucA, which results in a protein unable to bind AlgU and
thus overexpression of the AlgU regulon (15, 22, 40). AlgU controls the production of alginate
through a large 12 gene operon responsible for manufacture and transport of alginate
biosynthetic products (36, 40). In addition, AlgU regulates other genes like amrZ and algR,
which encode transcriptional regulators that directly control the alg operon (40, 56, 66 and
Figure 1).

Figure 1: A model depicting a genetic mutation that leads to mucoidy. In strain mucA22
(PDO300), AlgU is no longer bound by MucA and can regulate expression of genes leading to
overproduction of alginate.
The transcriptional regulator AlgR is required for alginate production, but also controls
additional virulence factors used during acute or chronic infections (32, 37, 51, 52). P.
aeruginosa and many pathogens use two-component systems (TCS) to translate extracellular
11

signals into changes in genetic expression (26). Typical TCS possess a transmembrane sensor
kinase and a cognate response regulator. AlgR is part of one such TCS, though it has been
shown to regulate some genes independent of its sensor kinase AlgZ (19, 68). AlgR directly
binds the promoter regions of genes it controls at a conserved CCGTTCGTC sequence (25, 35).
AlgR frequently binds multiple sequences upstream of controlled genes, and may control
expression through multimerization and subsequent alterations of chromosomal topography (25,
35).
AlgR was initially identified as an alginate regulator, but further studies illustrate its role
in initial attachment during infection (30, 44, 45). P. aeruginosa uses Type IV pili for twitching
motility, loose attachment, and biofilm formation (5, 9, 29, 53). AlgR is required for twitching
motility, and enacts its control by binding upstream of the fimU operon, which encodes several
proteins involved in construction and extrusion of Type IV pili (38, 64).
AlgR also influences quorum sensing. Quorum sensing is a population dependent cell
signaling mechanism used by bacteria to coordinate expression of collective virulence factors,
such as biofilm formation, pyocyanin production, and swarming motility (49, 50, 66). AlgR
suppresses quorum sensing directly at the rhlI promoter, preventing production of a C4homoserine lactone autoinducer (14, 45, 51). Rhamnolipids are secreted to facilitate swarming
motility and micro-colony formation, and are repressed by AlgR through direct binding at the
rhlA promoter (51, 52). AlgR’s control of quorum sensing components is important for biofilm
formation, and an algR mutant is defective in 6-day biofilm formation (45).
AlgR is also a negative regulator of Type III secretion (T3SS), and works in two separate
but coordinate ways to downregulate Type III gene expression (32, 34). First, AlgR represses
Vfr, a cAMP- binding protein that positively regulates Type III secretion (34). Additionally,
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AlgR negatively regulates Type III secretion by controlling expression of the RsmA/Y/Z system,
resulting in a net decrease of RsmA, which itself is required for full expression of the T3SS (32).
Further understanding of AlgR’s role in controlling rsmA expression is a current goal of this lab.
AlgR is a major virulence determinant, and algR mutants are attenuated for virulence in
acute septicemia and pneumonia models in mice (37). Interestingly, overexpressed algR
attenuates virulence and cell growth, suggesting that AlgR levels are tightly maintained within
the cell (37). The diverse array of virulence factors controlled by AlgR illustrates the protein’s
application in both acute and chronic infection backgrounds.
Gac/Rsm Regulatory System
Another important regulatory system sits at the intersection of acute and chronic
infection, and has been the source of much study and characterization in recent years. The
GacS/A two-component system is a phosphorelay system using posttranscriptional regulation to
affect gene expression. The GacS/A system is controlled by ancillary proteins. GacS, a hybrid
sensor kinase, is inhibited through dimerization with an orphan sensor kinase RetS, and inversely
supported through interaction with a second sensor kinase LadS (27, 28). LadS causes
autophosphorylation of GacS, followed by phosphotransfer to the response regulator GacA.
Phosphorylated GacA then directly controls the expression of two non-coding sRNAs, rsmY and
rsmZ. These are the only known genes GacA controls, and the sole purpose of the sRNAs
appears to be regulation of RsmA (6, 27, 28). RsmA, a post-transcriptional regulator in the CsrA
family of proteins, reciprocally controls expression of genes involved in acute and chronic
infection (6, 7, 26, 64). RsmA’s full characterization in P.aeruginosa is ongoing. RsmA binds
the GGA motifs present on the single stranded, exposed portions of RsmY/Z stemloops (27, 28).
Each sRNA is capable of binding 4-6 RsmA dimers, resulting in a net decrease of free RsmA in
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the cell (6, 53). When RsmA is not bound by the small RNAs it is free to enact its genetic
control at the post transcriptional level. A representation of components of the GacR/S/M
system is illustrated in Figure 2.

Figure 2: A model depicting the Gac/Rsm regulatory system. In acute strains (1), RsmA is free to
bind messages leading to negative regulation of Type VI Secretion and biofilms. In chronic
strains (2), phosphorylated GacA controls expression of rsmY/Z, which bind and inhibit RsmA.
RsmA and other CsrA family proteins control translation by directly binding mRNA at
conserved GGA motifs in the 5’ untranslated region of target genes (6, 64). Though direct,
positive regulation of messages occurs in E. coli CsrA, RsmA in P. aeruginosa has only been
shown to negatively regulate mRNA (6, 53, 64). RsmA dimers bind in close proximity to the
Shine-Dalgarno (SD) sequence and prevent translation through occlusion of the ribosome
binding site (2, 33, 43). Additionally, RsmA influences mRNA secondary structure to prevent
ribosomal recruitment (55, 64). A microarray performed on P. aeruginosa strain PAK showed
14

several genes are downregulated in an rsmA mutant (6). RsmA failed to bind these messages in
an mRNA binding assay, and positive regulation of gene expression by RsmA in P. aeruginosa
is believed to be indirect, perhaps by directly repressing expression of negative regulators for the
genes shown to be downregulated in the microarray..
RsmA directly represses several chronic virulence factors (21, 55, 64, 67). Type VI
Secretion (T6SS) is a chronic associated virulence factor used to attack neighboring bacteria with
a phage-tail like syringe. Type VI in P. aeruginosa damages competing bacteria through toxin
secretion as a retaliation for initial attack from competitors (6, 31, 46). RsmA represses
expression of the T6SS by direct binding to mRNA for multiple genes involved in formation of
the Type VI syringe (6). RsmA is also a negative regulator of genes involved in Psl
polysaccharide formation, and an rsmA mutant was able to hypersecrete Psl (24, 33).
RsmA is required for full expression of acute associated virulence factors like Type IV
pili and Type III Secretion, which it regulates in a currently unknown manner (6, 48). Since
direct positive regulation of mRNA has not been shown by RsmA, it is possible that RsmA
positively influences Type IV pili and Type III Secretion by directly inhibiting translation of a
negative transcriptional regulator of genes for Type IV Pili and Type III Secretion.
These lines of evidence suggest RsmA transitions the cell from expressing acute to
chronic virulence factors through genetic regulation at the post-transcriptional level. Further
evidence of this is the fact that an rsmA mutant was attenuated in a murine model of acute
pneumonia, but was able to better persist in a chronic model of infection (47). Given RsmA’s
global role in control of virulence factor gene expression, understanding the molecular and
biochemical signals involved in regulating rsmA expression may provide insight into the way P.
aeruginosa transitions from acute to chronic infection.
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Transcriptional Regulation of rsmA
The GacS/A proteins and the small RNAs RsmY and RsmZ are known to modulate levels
of free RsmA protein, but transcriptional regulation of rsmA in P. aeruginosa has not yet been
defined. A study of the RsmA homolog in E.coli, CsrA, identified five promoters (70). Two
promoters were shown to be under control of RpoS (σs), a stress-response sigma factor.
Expression from one of these promoters was shown to be indirectly dependent on CsrA itself.
Additionally, CsrA negatively regulates its own translation, similar to RsmA (64, 70). Given the
elaborate transcriptional control of csrA in E.coli, rsmA regulation in P. aeruginosa is likely to
be complex. Understanding rsmA regulation is a current goal of this lab. A primer extension on
rsmA was conducted previously to identify transcriptional start sites (69). An upstream promoter
was shown to be under the control of AlgU by showing reduced rsmA transcription and lower
RsmA protein levels in an algU mutant (69). Sequence adjacent to the AlgU dependent
promoter also showed a possible AlgR binding site (Figure 3).

5’-TTGACCGTTTGGCAGGAACTTTCATTCCGGCGGGACTG
GTCAATACTGGGTGAAGGATCGCGCTCTTGATTTCTGCGGATCCGCCGCCATTTCT
TTTTTGCAGACTGTTGTCCTGAAATATTCGCGTGAGGAGAAAGGAATG-3’
Figure 3: A possible AlgR binding site (underlined) exists on the rsmA promoter. Red sequence
denotes the -35 and -10 of the AlgU promoter. The blue ATG is the rsmA start codon.
Data from this lab and a study conducted by Intile, et al (32) suggests AlgR is responsible
for regulating rsmA expression, but a mechanism is currently unknown. One aim of this study
was to confirm AlgR regulation of rsmA transcription and to assess RsmA protein levels in algR
mutant strains. Overexpression of algR was attempted using a single copy chromosomal insert
under control of an inducible promoter as a tool to further analyze rsmA control by AlgR. The
second aim of this study was to describe a mechanism by which AlgR regulates rsmA, which
16

resulted in the hypothesis that AlgR binds the putative AlgR consensus sequence upstream of
rsmA. To show in vivo relevance of this control, we attempted site-directed mutagenesis on the
AlgR binding site within an rsmA-lacZ transcriptional fusion. Understanding the mechanism for
AlgR control of rsmA expands upon the novel regulatory interaction between AlgU and rsmA
described previously, and helps to illuminate the complex feedback patterns the cell uses to keep
RsmA levels controlled. The signals processed by many of these global regulatory systems are
unknown, and understanding the biochemical and genetic control of virulence factor gene
expression may help identify potential drug treatment targets. New drug targets capable of
eliminating P. aeruginosa infection will yield a better prognosis for the CF patient.
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CHAPTER 2
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
All strains and their sources are described in Appendix C. PAO1 was used as the acute
infecting wild type lab strain. A strain possessing a frameshift mutation in the mucA gene has a
defective anti-sigma factor and is mucoid. This strain, denoted mucA22 in the text was used as
the wild type mucoid strain. All Pseudomonas strains were maintained on PIA plates and grown
at 37˚ unless otherwise noted. In broth, Pseudomonas strains were grown in LB at 37˚ with ~200
RPM shaking for aeration unless otherwise noted. E. coli strains SM10, JM109 and NEB5α
were used to maintain and conjugate all plasmids for mating. Plasmids are listed in Appendix C.
SM10pRK2013 was used as a donor of the sex pilus when conjugating JM109. BL21 (DE3)
from New England Biolabs was used for protein expression and purification. E. coli strains were
grown on LB plates or broth at 37˚ unless stated otherwise. Antibiotic concentrations for
Pseudomonas and Escherichia growth media are available in Appendix A.
For long term storage of strains, a sterile loop was used to add the desired strain to 1.5 ml
10% skim milk or 20% glycerol in a cryotube and then stored at -80˚C.
Strains used in Western blot analysis possess a hemagluttinin epitope tag fused to RsmA
and were constructed previously by allelic exchange.
Quadparental Mating
For AlgR overexpression and complementation, quadparental conjugation was used to
introduce inducible algR into a neutral site on the P. aeruginosa chromosome downstream of the
glmS gene. The coding region of algR was cloned in frame downstream of the PBAD promoter of
pTJ1 previously in this lab (Appendix C). P. aeruginosa recipient strains were grown overnight

18

on PIA at 43˚ C. E. coli strains bearing pTJ1 or pTJ1algR were grown at 37˚ C. A strain bearing
pTNS3 helper plasmid was used to provide the integrase and was also grown at 37˚ C. pRK2013
was used to provide a sex pilus for pTJ1 and was grown at 30˚ C. Following overnight growth in
broth, 500 ul of each E. coli strain was pelleted at 4000 x g and resuspended in 100 ul LB.
Resuspended cells were combined in a single tube and a sterile stick was used to add P.
aeruginosa. The suspension was pipetted up and down to mix and spotted on LB overnight.
Successful integration of pTJ1 confers trimethoprim resistance, so LBtmp1500 (Appendix A) was
used to select for strains possessing successful integration. Strains were then screened via
colony PCR to confirm insertion.
β-galactosidase Assay
Strains to be assayed were grown overnight on PIA and a single colony was inoculated
into 5 ml LB broth and grown overnight at 200 RPM. Overnight culture (50 ul) was used to
inoculate another 5 ml LB, which was grown for 8 hours. From this 8-hour culture, 700 ul was
pelleted at 5000 x g and resuspended in 1 ml Z buffer + BME (Appendix B). Optical density
(O.D.) at 600 nm was taken and sample concentration was adjusted so OD600 was
0.4-1.0. SDS (50 ul of 0.1%) and 100 ul chloroform were added and the sample was vortexed for
15 seconds and allowed to sit 10 minutes. 500 ul of the lysate was added to a fresh tube with 300
ul Z buffer + BME. Z buffer with ortho-nitrophenyl-β-galactoside (200ul) was added to start the
colorimetric reaction. After a deep yellow color developed, the reaction was stopped with 500 ul
1 M Na2CO3 and the reaction time recorded. O.D. 420nm and 550nm were taken and used to
determine Miller Units as follows:
1000 x (O.D.420nm -1.75 x O.D. 550nm)
Time x Volume of sample (ml) x O. D. 600nm
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= Miller Units

Western Blotting
For RsmAHA: strains to be assayed were grown overnight in 5 ml LB. From the
overnight culture, 250 ul were used to inoculate 25 ml LB and grown 8 hours at 37˚ C at ~200
RPM. Entire cultures were spun at 5000 x g for 10 minutes and pellets were resuspended in 2.0
ml 0.85% NaCl in a 2.0 ml tube. For the reminder of the procedure, samples were kept on ice.
Samples were sonicated in 20 second bursts for a total of 1 minute each with 3-5 minute breaks
on ice between bursts. Lysates were centrifuged at 14000 x g for 10 minutes and 1 ml lysate was
removed to a new tube for quantification using the Bradford assay. Bradford reagent (5X) was
diluted to 1X in ddH2O and 3.5 ml were aliquoted into test tubes. Bovine serum albumin (BSA)
was used as a protein standard in the following concentrations: 2 mg/ml, 1 mg/ml, 0.5 mg/ml,
0.25 mg/ml, 0.125 mg/ml and 0.0625 mg/ml. A standard curve was generated using 30 ul of
BSA or protein sample, which were added to 3.5 ml 1X Bradford reagent and OD 595nm was
measured. A standard curve was generated in Microsoft Excel and trend line equation was used
to determine protein concentration. Only curves with R2 values of 0.98 or higher were used. 10
ug protein was mixed with 4X SDS-PAGE loading dye and boiled for 10 minutes before loading
into 15% SDS-PAGE with 4% stacking gel. The gel was run in Tris-glycine running buffer
(Appendix B) at 180 V for ~ 1.5 hours. Gel was removed from cassette and sandwiched between
double layer blotter paper soaked in transfer buffer (Appendix B) adjacent to a
polyvinylidenediflouride membrane that had been activated in methanol. Proteins were
transferred to the membrane at 150 mA for 1.5 hours. Membrane was blocked for ~2 hours in
blocking buffer and then split based on MW marker for separate staining of HA and OmlA
loading control. Primary antibody solution with either anti-HA or anti-OmlA (1:20,000) was
used overnight at 4˚ C on a rocker. The membrane was washed for 15 minutes 3 times in
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TBS-T. Anti-rabbit (OmlA) or anti-mouse (HA) secondary-antibody (1:20,000) solution
containing conjugated horseradish peroxidase was used for 1 hour at room temp. The membrane
was again washed 3 times and placed on a single layer of plastic wrap. Pierce ECL Western
Blotting Detection was used by mixing 3 ml of Substrate A with 75 ul Substrate B and treating
membrane for 5 minutes before visualization in ProteinSimple FlourChem M CCD camera.
Twitching Assay
A sterile toothpick was dabbed onto a single colony and stabbed into 1% LB agar with or
without arabinose (Appendix A). Plates were grown upside down at 30˚ C for 48 hours. Agar
was removed and the bottom of plate was flooded with 0.1% crystal violet for 1 minute, then
rinsed and allowed to dry. Twitching ability was measured as the diameter (mm) that each strain
had migrated from the initial stab line.
Colony PCR
To confirm the presence of fusions or expression vectors, PCR was performed as follows:
A toothpick was used to dab a single colony which was dispersed into 50 ul sterile, double
distilled (sdd) H2O in a microtube. For a 25 ul reaction, the following was assembled (Table 1):
Table 1: PCR master mix
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The master mix (23 ul) was aliquoted into PCR tubes containing 2 ul template. 30 ul mineral oil
was added and tubes were placed in a pre-heated thermal cycler with following run settings (see
Table 2):
Table 2: PCR thermal cycler settings

Following the Final Extension, tubes were stored at 4˚ and a 4-6 ul sample was analyzed on an
agarose gel.

AlgR Purification
Transformation
Prior to this study, the complete sequence for algR was cloned in frame within the pGEX4T-2 expression vector (Appendix C) and its sequence was verified. A plasmid prep was
completed previously and was used for transformation into BL21 expression cells per New
England Biolabs manufacturer’s protocol. One tube containing 50 ul NEB BL21 cells was
removed from -80˚ storage and placed on ice for 8 minutes. The plasmid prep was quantified
using absorbance at O.D.600 nm and 100 ng of plasmid was added to the tube and flicked 3-4
times to gently mix. The tube was placed back on ice for 20 minutes and then heat shocked in a
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42˚ C water bath for exactly 10 seconds. In subsequent cases where lab-prepared chemically
competent BL21 cells were used, the heat shock was carried out for 45 seconds to 1 minute. The
tube was placed back on ice for 2 minutes and 950 ul SOC (Appendix A) was added. Cells were
rescued at 37˚ C with high aeration for one hour. Several dilutions of the cells were plated onto
LBamp100 plates and grown overnight at 37˚ C.
Plasmid Prep Using Alkaline Lysis
To confirm correct transformation, a single colony transformant was used to inoculate 5
ml LBamp100 broth and grown overnight. This culture was used to obtain a purified plasmid for
further analysis to confirm the algR insert. The entire 5 ml culture was pelleted at 5000 x g for
10 minutes and resuspended in 150 ul TE with 2 ul RNAse A. Just prior to use, a solution of 0.2
N NaOH/ 1% SDS was prepared. Lysis solution (300 ul) was added to the cells and mixed by
inverting the tube 4-6 times. Tubes were placed on ice for 5 minutes, then 250 ul 3M potassium
acetate was added and tube inverted 6 times, then again incubated on ice for 5 minutes. To
separate the fractions, tubes were spun in centrifuge at 14,000 x g for 10 minutes. The
supernatant was removed to a new tube and an equal volume of 24:25:1 chloroform, phenol and
isoamyl alcohol (CPI) was added to denature and remove the protein before spinning again for
10 minutes. The top phase was removed to a new tube and equal volume of chloroform/isoamyl
alcohol (24:1) was added to extract the phenol. The tubes were again centrifuged for 10 minutes
and the supernatant was removed to a new tube. Cold 95% ethanol (EtOH) was added to
precipitate the plasmid and the tube was incubated 10 minutes on ice before again spinning for
10 minutes. The EtOH was carefully extracted and the pellet was allowed to dry briefly before
adding 1 ml 70% cold EtOH. The tube was centrifuged a final time for 5 minutes before
removing EtOH and allowing pellet to dry by laying tube open on a kimwipe. Pellets were
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resuspended in 50 ul sddH2O and quantified spectrophotometrically based on absorbance at O.D.
260nm.
Restriction Digest
Digestion of purified plasmid was performed to confirm presence of algR sized insert.
Purified plasmid was diluted to ~100 ng/ul and 2 ul was added to a centrifuge tube. 2 ul NEB
10X CutSmart Buffer and 14 ul sddH2O were added. Restriction enzymes (1 ul) Not1-HF and
Sal1-HF were added and tube was flicked to mix. The 20 ul reaction was incubated at 37˚ C at
least two hours before inactivation of enzymes in 65˚ C water bath for 5 minutes. Digests were
run on agarose gel to observe an algR insert from purified pGEXalgR (Appendix F).
Inducing Protein Expression
A single colony transformant was used to inoculate two separate 1.5 ml LBamp100 broths
and was grown overnight at room temperature with high aeration. The next day, the entire
cultures were used to inoculate two 150 ml LBamp50 in a 500 ml flask. These cultures were
placed at 37˚ C under high aeration until growth reached O.D.600 of ~0.45. IPTG at 0.5 uM was
then used to induce one of the cultures, then cultures were moved to a room temperature shaker.
Samples were taken at different time points to determine optimal expression. The samples (10
ml) were taken from the cultures at the following times: Pre-induction, followed by 2, 4 and 8
hours post-induction. These 10 ml samples were pelleted at 4000 x g for 5 minutes before
resuspension in 0.85% NaCl. Sonication was conducted the same as for Western Blotting
samples. Lysates were added in equal volumes to a 7% SDS-PAGE and run at 180 V for 1 hour.
The gel was removed and stained in a Pyrex dish with 25 ml 1% Coomassie staining solution
(Appendix B) overnight. The gel was destained using SDS-PAGE destaining solution

24

(Appendix B) for 1 hour with several kimwipes added to absorb the stain, then was visualized on
a ProteinSimple FlourChem M CCD camera.
Protein Purification Using GST Spin Columns
Culture conditions above were used with 0.5 uM IPTG induction and cells were allowed
to grow for 4 hours. Four separate 20 ml samples were taken from the flask and pelleted at 4000
x g for 5 minutes. Each pellet was washed with 1X cold PBS and resuspended in 2 ml cold lysis
buffer (Appendix B). For the remaining steps, cells were kept on ice. Samples were sonicated in
2 ml tubes using one second sonication bursts at 40% amplitude for a total of thirty seconds
sonication. This was repeated three times and tubes were spun at 15,000 x g for 10 minutes.
Supernatant was removed to a new tube and used to pass over the GST spin columns. Pierce (0.2
ml resin bed volume) GST-spin columns were used to bind the AlgR-GST fusion. Two columns
were used for each round to balance out the centrifuge and increase yield. All further steps were
performed at room temperature while lysates were kept on ice. The lysate obtained above
(usually about 4 ml from two samples) was passed in 500 ul aliquots (of 400 ul lysate and 100 ul
GST buffer) into each column. Columns were plugged and taped to a rocker for 30-45 minutes
before spinning out the lysate at 700 x g for 2 minutes. Fractions were saved for downstream
analysis. After the final aliquot was passed over column, the column was washed 3-5 times with
400 ul GST wash buffer and plugged. A 50 ul tube of thrombin (1 unit/ul) was thawed on ice
and 950 ul cold PBS (Appendix B) was added. Each column was washed 2x with cold PBS
before 400 ul of the thrombin mixture was added to each tube. Tubes were kept at gentle
rotation at room temp overnight (about 12 hours). The flow through was collected and
immediately aliquoted into microtubes in 10 ul volumes. 30 ul 4X protein storage buffer
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(Appendix B) was added and tubes were immediately placed at -20˚ C for storage. Several
fractions were analyzed on Coomassie stained SDS-PAGE and are shown in the Chapter 3.
Quantification of the Purified Lysate
Purified diluted fractions were quantified using the Bradford assay as well as absorbance
at O.D.280nm and concentration was found to be ~1 mg/ml in 800 ul total volume purified. The
purified flow-through (10 ul) was diluted into 30 ul 4X Storage Buffer (Appendix B) leaving 10
ug per stock. According to visual estimation from SDS-PAGE, about 75% percent of the
fraction was AlgR, giving a dilution factor of 0.75, or 7500 ng AlgR per 40 ul stock. Since the
diluted stocks (to eliminate unspecific proteins) were diluted 1:10, this gave ~750 ng AlgR per
stock. As AlgR is 26.7 kDa this gives a 700 nM concentration of AlgR in each 40 ul stock. For
binding reactions: (700nM stock)(2 ul) = (x nM)(20 ul binding volume) = 70 nM AlgR/ 2 ul for
use in binding reactions.
Electrophoretic Mobility Shift Assay (EMSA)
Generating Unlabeled Probes
For the pscE/F gene, 50 base-pair (bp) annealed oligos were used as the binding target.
pscE/FGS1F (Appendix C) was 3’-biotinylated (see below) and then mixed in an annealing
reaction with the unlabeled complementary oligo to generate a double stranded probe as follows:
Each probe was adjusted to 1 uM in TNE buffer (Appendix B). A 20 ul volume of each probe
was combined in a microcentrifuge tube and placed in a 95˚ heat block for ten minutes. Power to
the heat block was removed until it cooled to room temperature, then annealed probes were
stored at -20˚ C.
The rsmA and algD probes were generated by PCR amplification of ~160 bp regions of
their respective promoters, followed by gel extraction and 3’ biotin end labeling of the DNA.
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Sequences of annealed oligos for pscE/F and primers used to amplify promoters for algD and
rsmA are listed in Appendix C.
Biotin 3’ End Labeling
Gel extracted PCR products and single oligos were labeled for visualization in the
EMSAs using ThermoScientific 3’ Biotin End DNA Labeling Kit. For labeling reactions: All kit
components (except TdT) were thawed on ice. Immediately prior to making reaction mix,
terminal-deoxynucleotidyl-transferase (TdT) was removed from freezer and diluted to a conc. of
2 U/ul (ex.: 1 ul TdT Buffer + 3.5 ul sddH2O + 0.5 ul TdT = 5 ul TdT at 2 U/ul). The following
components were assembled in a centrifuge tube (see Table 3):
Table 3: Biotin 3’ End Labeling reaction mix

After 30 minutes, the reaction was halted by adding 2.5 ul 0.5M EDTA. The TdT was extracted
by adding 50 ul CI (24:1) and vortexing, followed by centrifugation to separate the phases. The
aqueous layer was decanted, quantified on ThermoFisher NanoDrop (O.D. 260nm) and stored at 20˚C until use in EMSA.
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Quantifying Probes for Use in Binding Reactions
For determining the concentration of annealed oligos:
100 nM conc. of the forward oligo was used in the biotinylation reaction. Manufacturer
estimates ~80% labeling efficiency with this method, leaving 80 nM concentration following
labeling reaction. An 80 nM stock was made of complementary R oligo and annealing reaction
was set up using equal amounts of each primer to give final concentration of 80 nM following
annealing. Following absorbance reading at O.D. 260 nm, dilutions were made at 10 ng/ul in 20
ul stocks, or 200 ng/ stock. 200 ng/ 20 ul stock = 6 pmoles (for 50 bp) / 20 ul stock, or 0.3
pmoles/ul. In each binding reaction, 0.25 ul was used, so ~225 fmols/ 20 ul reaction was present.
Concentration of PCR generated probes:
PCR amplicons were gel extracted and quantified, then dilutions were created as above to
generate a ~10 ng / ul stock in 20 ul. For this 200 ng at 160 bp, there are roughly 2 pmoles/ 20 ul
or 100 fmoles / ul. Since 0.25 ul was used in each binding reaction, ~25 fmoles labeled probe
were used per assay.
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Gel Shift (EMSA)
For all EMSAs, components of the ThermoScientific LightShift EMSA Kit were used for
binding reactions and visualization. Following successful use of the control components,
purified AlgR was used in a binding reaction with different labeled probes. All components
except AlgR stocks were thawed on ice and the following reaction mix was added to each tube:
Table 4: EMSA Binding Reaction components

Reagents were added in the order listed above and allowed to incubate at room temperature for
30 minutes. Meanwhile, a prepared 5% polyacrylamide TBE gel (Appendix B) was placed in a
chamber with cold 0.5X TBE (Appendix B) as a running buffer. The gel was pre-run for 30
minutes during the binding reaction at 100V. 5 ul of 5X Blue Juice (Appendix B) was added to
each reaction tube and slowly pipetted to mix. The entire reaction mix was loaded onto the gel
and run for an hour. The probes were then transferred to a nylon membrane that was soaked in
0.5X TBE using a semi-dry apparatus. The gel was sandwiched on top of the nylon and between
a soaked blotter paper bilayer. The probes were transferred for 30 minutes at 380 mA. The
membrane was removed, dabbed on a kimwipe and crosslinked by exposure to 120 mJ of UV
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light in a crosslinker at 254 nm for ~60 seconds. The membrane was then stored or immediately
visualized.
EMSA Chemiluminescent Detection
All components for nucleic acid detection came with the ThermoScientific
Chemiluminescent Detection Kit. Blocking buffer and 4X Wash buffer were warmed in a 42˚
water bath until all particulate had dissolved. All other components were kept at 4˚ C until ready
for use. To block the membrane, 15 ml Blocking buffer was added to a clean tray and the
membrane was rocked for 15 minutes. A conjugate/blocking buffer solution was prepared by
adding 50 ul Streptavidin-HRP Conjugate to 15 ml Blocking buffer. This was added to the
membrane and rocked for another 15 minutes. Membrane was then removed to a clean tray and
rinsed briefly with 15 ml 1X Wash buffer. Four additional wash steps were performed for 5
minutes each. 30 ml Substrate Equilibration Buffer was added to a clean tray and the membrane
was treated for 5 minutes. During this treatment, a substrate visualization solution was prepared
by adding 3 ml Luminol Enhancer to 3 ml Stable Peroxide. The membrane was removed from
buffer, dabbed on a kimwipe and placed on plastic wrap. Visualization solution was added for 5
minutes. The membrane was sealed in plastic wrap and visualized using ProteinSimple
FlourChem M CCD on the chemiluminescent setting.
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Statistical Analysis
For the transcriptional fusions, experiments were performed in triplicate and subject to
mean, standard deviation, and standard error analysis in Microsoft Excel. Standard error is
depicted on each graph using positive error bars. To determine statistically significant difference
between more than two groups, one-way ANOVA analysis was performed in Excel. To
determine significance between two groups, a post-hoc two-tailed unpaired t-test with Bonferroni
correction was performed in Excel . “***” denotes p value < 0.001 between respective group
means.
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CHAPTER 3
RESULTS
Induced algR Expression Restores Twitching Motility to an algR Mutant
Previous studies by this lab and others identified AlgR as a regulator of rsmA expression
(32). One goal of this study was to use inducible algR expression to further understand AlgR’s
effect on rsmA. Expressed algR was used by Intile, et al to show an increase in rsmA activity
using transcriptional fusions (32). To measure rsmA activity, this study used transcriptional
fusions with the rsmA promoter containing the putative AlgR binding site fused to lacZ. Another
way to measure RsmA is through Western blotting to observe changes in RsmA protein levels.
Overexpression was attempted by placing an inducible Tn7-based algR expression construct into
the chromosome of strains possessing either an rsmA-lacZ transcriptional fusion or HA-tagged
RsmA.
Previously in this lab, the algR open-reading frame was cloned into the pTJ1 expression
vector (Appendix C), which can be integrated into an att:Tn7 site on the P. aeruginosa
chromosome downstream of the highly conserved glmS gene. Quadparental mating (Chapter 2)
was used to introduce pTJ1algR into strains bearing the rsmA-lacZ transcriptional fusion, as well
as strains with an epitope-tagged RsmA-HA generated previously. Colony PCR was used to
verify correct insertion of the complementation vector and is shown in Figure 4.
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Figure 4: Conjugated strains possess pAlgR. Colony PCR was performed using primers
pHERDSF and pTJ1R (Appendix C), which flank regions of the multiple cloning site for pTJ1.
The second lane of the gel in Figure 4 represents amplification from JM109 cells
possessing the pAlgR construct and amplifies a ~700 bp band. Cells bearing the empty vector
produce a much smaller (~50 bp) band in the next lane. Successfully conjugated P. aeruginosa
strains produce a band that corresponds in size to the positive control, indicating pAlgR is present
in these strains.
After successful conjugation, it was necessary to determine whether or not the algR
overexpression system was able to restore an AlgR dependent phenotype to an algR mutant, thus
confirming that algR was correctly being induced in the presence of arabinose. AlgR regulates
twitching motility/Type IV pili by direct binding upstream of the fimUpilVWXY1Y2E operon,
and the twitching phenotype is lost in an algR mutant (38, 64). Production of alginate in the
mucoid strains is another phenotype dependent on AlgR, but complementation and
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overexpression studies have shown that this phenotype is sensitive, and that algR overexpression
will not result in restoration of alginate production (18, 38). A subsurface twitching assay was
thus performed to investigate the ability of the algR overexpressing strains to restore twitching
motility.

Figure 5: pAlgR restores twitching motility to an algR mutant. Strains above were grown on 1%
LB agar with 1% arabinose for 48 hours and twitching zones were stained with crystal violet.
Table 5: Twitching diameter in wild type, mutant and complement strains
Strain

Twitching (mm) on 1% LB

Twitching (mm) w/1% arab.

PAO1

13 ± 1

11 ± 0.3

PAO1ΔalgR

2

2 ± 0.16

ΔalgR + pAlgR

6 ± 0.7

16 ± 2

ΔalgR +pTJ1

6 ± 0.3

5
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The results of the assay (Figure 5 and Table 5) show that the wild-type PAO1 is capable
of twitching motility on both media with and without 1% arabinose. PAO1∆algR is defective for
twitching motility, and this is restored by induced expression of pAlgR. The complemented
strain (ΔalgR+pAlgR) also shows twitching on medium without arabinose, indicating transient
induction of pAlgR. Some twitching motility is also restored to ∆algR+pTJ1 on media with and
without arabinose. This may indicate that the empty vector alone restores twitching motility.
However, the pTJ1 vector inserts into a chromosomally neutral location and this has not been
shown to disrupt expression (12, 16). It is possible that the pTJ1 empty vector was conjugated
into a mixed culture of ΔalgR and an unknown contaminant that was capable of twitching
motility, thus explaining the erroneous twitching results seen in ΔalgR+pTJ1. This would
explain the unexpected twitching despite PCR verified presence of only the empty vector.
Restoration of twitching motility is observed in the algR mutant bearing pAlgR. In addition, this
increase is responsive to arabinose, which indicates that despite transient expression and
apparent partial restoration by the empty vector, pAlgR may be useful for investigating AlgR
control of rsmA. Strains with algR deletions also possess a defect in swarming motility (52, 64).
A swarming assay on M9 Minimal Media with the strains above, combined with re-conjugation
with the empty vector could provide clarification for the misleading ability of ΔalgR+pTJ1 to
twitch.
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mucA22∆algR Has a Defect in rsmA Expression That is Not Restored by pAlgR
This lab and Intile, et al (32) used transcriptional fusions to show that rsmA expression
decreased in an algR mutant. The fusions used by this lab include both rsmA promoters
identified in the primer extension of rsmA completed in a previous study (69). First, we sought
to confirm an increase in rsmA expression previously seen in mucA defective strains (32, 69). In
addition, rsmA expression was measured in algR mutants in PAO1 and mucA22 and compared to
wild type (Figure 6).

Figure 6: algR mutants have decreased rsmA expression. Cultures were grown for 8-hours and
β-galactosidase assay was performed with ONPG and quantified in Miller Units. “***” denotes
p-value < 0.001.
The results of Figure 6 show that rsmA expression is increased in the mucoid
background, which agrees with previous studies (32, 69). This increase seen in mucA22 is
abrogated in the mucA22ΔalgR strain, suggesting that AlgR may be required for full rsmA
expression in mucA22. A slight decrease in rsmA expression was seen in ΔalgR compared to
PAO1, though these results have yet to be confirmed in further study. Since it appeared AlgR
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was required for full rsmA expression in mucA22, expression of pAlgR was hypothesized to
result in an increase in rsmA. pAlgR was integrated into PAO1rsmA-lacZ as described in
Chapter 2, and β-galactosidase activity was measured to determine inducible algR’s effect on
rsmA transcription (Figure 7)..

Figure 7: pAlgR does not increase rsmA expression in PAO1. Cultures were grown as in Figure
6, and pAlgR was induced with 1% arabinose at log phase and grown to 8 hours before
measuring β-galactosidase. “***” denotes p-value < 0.001.
The results in Figure 7 show that no increase in rsmA expression occurs with induced
expression of algR in PAO1. In fact, expression is slightly reduced from wild-type. If
overexpressed algR is unable to increase rsmA expression in PAO1, it is possible that rsmA may
be sensitive to optimal levels of AlgR that are disrupted with overexpression. In addition, this
promoter may require a combined effect of AlgU and AlgR. To examine this further,
complementation studies were attempted in mucA22ΔalgRrsmA-lacZ to look for restoration of
rsmA expression (Figure 8).
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Figure 8: pAlgR does not complement rsmA expression loss in mucA22ΔalgR. pAlgR was
induced with 1% arabinose at log phase and grown to 8 hours before measuring βgalactosidase. “***” denotes p-value < 0.001.
The results of Figure 8 show that there is a drastic loss of rsmA expression in
mucA22ΔalgR that is not restored by pAlgR. Taken together, the results of Figures 6, 7 and 8
suggest that an algR mutant in the mucoid background has diminished rsmA expression. This
may indicate AlgR control of rsmA, but overexpression and complementation with pAlgR was
unable to increase rsmA activity in our strains, indicating further study is needed to determine
how AlgR is controlling rsmA expression in mucA22. The inability of pAlgR to increase rsmA is
addressed further in Chapter 4.
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algR Mutants Possess Decreased Levels of RsmA-HA
The results of the transcriptional fusions suggest algR mutants have decreased rsmA
transcription, and that overexpressing algR does not increase rsmA expression in PAO1 or
complement the loss in mucA22ΔalgR. To determine if protein levels of RsmA are also affected
by algR mutation, an epitope-tagged RsmA-HA constructed previously was used to analyze
RsmA in various strains. The epitope tag has no adverse effect on RsmA’s function because
mucA22rsmAHA remains mucoid, a phenotype lost in mucA22∆rsmA (unpublished, data not
show). Culture conditions used in Figures 6,7 and 8 were replicated to perform Western blotting
and observe RsmA-HA. Overexpression of algR in PAO1 and complementation in
mucA22ΔalgR was again investigated for an ability to increase or restore RsmA levels, thus
directly implicating AlgR in control of rsmA.
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Figure 9: algR mutants have decreased RsmAHA protein levels. Strains were grown in LB broth
for 8 hours and levels of RsmAHA were measured by Western blot. A membrane protein (OmlA)
was used as a loading control.
Two separate membranes were used to accommodate all of the strains used for analysis
of RsmA-HA. In Figure 9 (A) there was evidence that PAO1∆algR has diminished RsmA-HA
levels compared to wild-type. This loss is more drastic than the decrease in rsmA expression
seen in Figure 6. This result is being investigated further and has yet to be confirmed. A
previous study indicates mucA22 possesses higher levels of RsmA-HA compared to PAO1 (62).
The results in Figure 9 (B) show a small increase of RsmA-HA in mucA22, but at a less drastic
level than was previously observed and certainly less than is shown by the fusions in Figure 6.
mucA22∆algR possessed a decrease in RsmA-HA compared to mucA22, but more accurate
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controls and stringent protein loading must be used in the future, and at this time this remains
preliminary data. In addition, densitometry could be performed on the blot to obtain quantitative
results for the protein levels standardized to the OmlA loading control. This may clarify some of
the perceived differences in RsmA-HA between the strains. Induced expression of pAlgR had no
significant effect on RsmA-HA protein levels in either strain, which mimics the fusions and is
addressed in Chapter 4.
An AlgR Extract Binds the rsmA Promoter
The defect in rsmA expression seen by Intile et al (32) and this lab indicate AlgR has an
effect on rsmA in the cell. However, the mechanism of control remained to be elucidated, and it
was unclear whether the AlgR effect on rsmA was direct or indirect. The primer extension
completed by Stacey, et al identified a putative AlgR binding site adjacent to an AlgU dependent
promoter for rsmA (62). It was thus hypothesized that AlgR may bind the promoter and regulate
rsmA directly. To test this, an extract containing AlgR was obtained and used in an
electrophoretic mobility shift assay (EMSA) on a labeled section of the rsmA promoter
containing the putative AlgR binding site.
Expression of an AlgR-GST Fusion is Induced in BL21(DE3)
To determine if AlgR bound the rsmA promoter, gel shift studies were initiated. First,
purified AlgR was obtained for use in gel shift experiments. Previous work in this lab cloned the
complete open reading frame for algR into the pGEX4T-2 expression vector (Appendix C). A
purified plasmid prep of this was created and sequence verified, then used in this study to
overexpress an AlgR-GST fusion. AlgR was then separated from GST using thrombin cleavage.
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The plasmid prep above was quantified and 100 ng (determined using absorbance at
OD600nm) was transformed into BL21 (DE3) cells from New England Biolabs, described in
detail in Chapter 2. Expression conditions listed in Chapter 2 were utilized and SDS-PAGE was
conducted followed by Coomassie staining to determine if the AlgR-GST fusion was being
expressed in a quantity sufficient to warrant further purification.

Figure 10: A 53 kDa protein is present in induced cultures. Lysates containing 10 ug total cell
protein from induced and non-induced cultures were resolved on 7% SDS-PAGE and stained
with Coomassie Brilliant Blue.
Protein lysates from induced cultures displayed specific, increasing expression of a 54kDa protein. AlgR and glutathione-s-transferase were fused for purification, and each is ~27
kDa. Induction of cells containing the empty vector was not conducted, but the increase in
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quantity of a protein corresponding to the size of an AlgR-GST fusion was not present in
uninduced cultures, indicating tight control over transient expression from this vector.
A 27 kDa Protein is Present Following Column Purification
The results of Figure 7 were enough evidence to proceed with further purification, using
GST-Spin Columns from ThermoScientific as described in Chapter 2. Multiple fractions from
this process are indicated in Figure 8.

Figure 11: A lysate containing a 27 kDa protein is purified from the spin columns. Various
fractions from the column purification process were resolved on 10% SDS-PAGE and
Coomassie stained to view proteins present from each stage.
Lysates from induced cultures were passed over the columns and the flow-through is
shown in the first two lanes following the molecular weight marker. Following three washes,
little protein was observed. A fourth wash was performed before incubation with thrombin
overnight to cleave AlgR from the GST moiety. Following thrombin treatment, a large amount
of protein at 27 kDa was observed, in addition to several other proteins of multiple sizes. A
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significant amount of protein was present at 20 kDa, and other proteins were present in trace
amounts. This 20 kDa protein may represent enzymatic breakdown of AlgR that occurred in the
column overnight. To reduce the amount of proteins not corresponding to the size of AlgR, the
eluate was diluted 1:10 in sterile PBS then stored in 4X Protein Storage Buffer (Appendix B) at
-20˚ C. Lanes 8 and 9 in Figure 8 show that following the dilution, the two proteins in
abundance were at 27 and 20 kDa, with the 27 kDa protein in excess. Lane 10 indicated no
breakdown of the 27 kDa occurred after addition of 4X Storage Buffer.
Western Blotting Confirms AlgR is Purified
Western blot analysis was performed on the purified fraction in order to show that AlgR
was the 27 kDa protein.

Figure 12: Western blot confirms AlgR was the major protein purified. Following thrombin
cleavage, 10 ul of eluate and 10 ul post-wash flow-through were resolved on 10% SDS-PAGE
and treated with polyclonal antibody to AlgR. 10 ug whole-cell lysate from PAO1 and
PAO1ΔalgR were also run as a reference for AlgR.
The results above show that polyclonal antibody for AlgR did not bind anything in a lane
containing a lysate from PAO1ΔalgR but bound a protein present at ~27 kDa in PAO1 and
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within the purified fraction. These results indicate AlgR was the 27kDa protein. Since AlgR
was shown to be present in the purified stocks, gel shift studies were pursued.
A Purified Fraction Containing AlgR Binds algD and rsmA but not pscE/F
Before testing the AlgR extract’s ability to bind the rsmA promoter, it was necessary to
ensure that the AlgR extract did not bind a probe nonspecifically. In addition, the extract was
tested for binding to a section of DNA previously shown to be controlled by AlgR (44). Since
the purified extract contained proteins not corresponding to the size of AlgR, results of these
control gel shifts could provide evidence that AlgR was binding correctly, and thus warrant
further investigation of the extract’s ability to bind rsmA.
The purified containing AlgR was mixed in a binding reaction with annealed oligos or
PCR probes that were 3’ end labeled with biotin by TdT (Chapter 2). AlgR was shown in a
previous study not to bind to a site overlapping the pscE/F genes (52), and a labeled, 50-base
pair probe (sequence available in Appendix C) representing this region was used as a negative
control to eliminate the possibility that the protein extract bound nonspecifically. The algD gene
of the alginate biosynthetic operon has been shown to be bound by AlgR and was thus used as
positive control (44). PCR was used to generate probes for algD and rsmA with primers listed in
Appendix C, and this yielded a larger probe (~160 bp) than the negative control. Using PCR to
generate these probes afforded the ability to better specify the region bound by AlgR by
narrowing the size of the probe in future assays using primers already available to the lab. The
rsmA probe contained both promoters and the putative AlgR binding site. This probe was
generated and labeled as depicted in Figure 13 below:
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Figure 13: PCR amplification and end-labeling generate probes for EMSA. Primers flanking the
rsmA promoter (RSDMF and rsmAGS1R2) were used to create a PCR product that was
biotinylated using terminal-deoxynucleotidyl transferase.

46

To make sure that non-specific proteins present in the purified extract did not cause
binding to non-specific probes, a gel shift was performed on pscE/F and is depicted below in
Figure 11.

Figure 14: AlgR does not bind the pscE/F probe at 100 nM. ~200 fmols pscE/F probe were
mixed with 50 and 100 nM AlgR purified fraction to determine the extract’s ability to bind a
gene known not to be regulated by AlgR.
The pscE/F probe (~200 fmols) was not bound by AlgR at 50 or 100 nM (conc.
determined using methods in Chapter 2). These binding reactions were run on a separate gel
from the algD and rsmA reaction due to the size difference in the probes, which necessitated
construction of a higher percentage polyacrylamide gel for proper resolution of the ~50 bp
pscE/F probes. The concentration of AlgR in Figure 11 is less than that shown to bind rsmA
(Figure 12), but other binding reactions conducted in the lab displayed the extract’s inability to
bind this probe at higher concentrations, and 100 nM was deemed relevant because that is the
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concentration seen binding algD below. The inability of the AlgR containing fraction to bind
pscE/F warranted its use in further assays to test its ability to bind the rsmA promoter.
The extract was next tested for its ability to bind the rsmA probe containing the potential
AlgR binding site. To ensure that the AlgR containing fraction was capable of binding a gene
known to be directly regulated by AlgR, the algD probe was included on the same gel as rsmA to
verify the extract’s correct binding ability.

Figure 15: AlgR bound the algD probe at 100 nM and rsmA probe at 200 nM. Probe
concentration was ~25 fmols.
The results above indicate the ability of the purified fraction to bind and shift algD
similar to that of other studies (44). Titration of the protein extract was conducted in binding
reactions with the rsmA probe, and complete binding occurred at a 200 nM concentration of
protein. This interaction was shown to be specific when excess amounts of unlabeled rsmA
probe were used to abrogate the shift, as depicted in the last two lanes of Figure 12. These
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results indicate that the AlgR containing fraction correctly bound a gene known to be regulated
by AlgR, and specific binding also occurred to the rsmA probe.
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CHAPTER 4
DISCUSSION
AlgR and rsmA Regulation
P. aeruginosa’s ability to transition from acute to chronic infection within the cystic
fibrosis lung is crucial for this pathogen’s ability to cause severe mortality for these patients. P.
aeruginosa uses complex and diverse genetic regulation to control gene expression for different
virulence factors. While regulatory systems used during acute infection are becoming well
understood, much remains unclear about regulation of chronic virulence factors and the genetic
regulation involved in the switch to chronic infection. Characterizing pathways involved in
pushing the cell into the mucoid phenotype can yield clues as to the signals processed by P.
aeruginosa to induce expression of chronic virulence factors. In addition, interruption of these
vital pathways may serve as a future drug target.
AlgR is a transcriptional regulatory protein required for alginate production, and is active
in chronic strains (6, 7, 26, 64). RsmA is a post-transcriptional regulatory protein that
encourages expression of acute associated virulence factors (32, 37, 51, 52). These two proteins
serve crucial regulatory roles, and were previously thought to exist as part of two separate
regulatory pathways. Recently, however, transcriptional analysis of rsmA has shown a novel
interaction between these two global systems and has given clues as to how P. aeruginosa
controls expression of virulence factors in the mucoid strains (32, 62).
A previous study by Intile, et al (32) demonstrated AlgR control of rsmA expression, but
a mechanism was not determined. A primer extension of rsmA was conducted by Stacey, et al
(62), and identified a possible AlgR binding site adjacent to an AlgU dependent promoter.
Control of P. aeruginosa RsmA has previously been shown to occur by production of RsmY and
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RsmZ, sRNAs that bind RsmA and thus modulate its ability to reach its mRNA regulatory
targets (7). Control of rsmA at the transcriptional level, however, remains unclear. The
AlgU/AlgR control of rsmA expression presented by this lab suggests that known regulatory
pathways involved in alginate production tune rsmA expression. This illustrates a previously
unknown interaction between two global systems that regulate virulence factor gene expression
in P. aeruginosa. The goal of this study was to elaborate on the finding that AlgR controls rsmA
expression and to determine the mechanism. Expression of algR was investigated for having an
effect on rsmA transcription and protein levels. In addition, a purified extract containing AlgR
was used in a gel shift to test its ability to bind the rsmA promoter.
RsmA promoter activity in vivo was measured using a previously constructed rsmA-lacZ
transcriptional fusion as a readout for rsmA expression. Results from Figures 6, 7 and 8 showed
that mucA22rsmA-lacZ expression is elevated compared to PAO1rsmA-lacZ, which agrees with
the data from Intile, et al and Stacey, et al that shows rsmA transcription is elevated in a mucA
mutant (32, 62). Deletion of algR in the mucA22 background showed decreased rsmA
expression. Western blotting of epitope tagged RsmA-HA was used to compare RsmA protein
levels. Results of the Western blot analysis in Figure 9 are suspect due to the lack of RsmA-HA
increase in mucA22 shown by other studies in this lab. Loading errors may explain the deviation
between the Western blots and the transcriptional fusions. Though the algR mutants show less
RsmA-HA than either wild-type, these results need further study before AlgR can be said to
control RsmA protein levels.
Additional methods could be used to measure rsmA expression in an algR mutant, such as
directly measuring levels of mRNA in a Northern blot or quantitative real-time PCR to measure
fold changes in rsmA expression in a mucA22ΔalgR strain compared to the wild-type mucoid
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strain. Results from those studies could provide further evidence that an rsmA expression defect
is AlgR dependent.
Since a loss of rsmA expression was seen in mucA22ΔalgRrsmA-lacZ, it was
hypothesized that expression of algR would show an increase in rsmA activity in PAO1
rsmA-lacZ and PAO1RsmA-HA. Overexpressing algR in any background failed to increase
rsmA transcription or protein levels, contrary to the results of Intile, et al (32). The pAlgR
overexpression vector was able to restore twitching to an algR mutant (Figure 4 and Table 5),
which suggests that algR was correctly being induced during the twitching assay. It is possible
that induction differences occurred between the twitching assay, which was performed on solid
media, compared with the β-galactosidase assay and Western blots, which were performed from
broth cultures. Investigation into different concentrations and timing of arabinose induction with
the strains used in this study could potentially show an AlgR-dependent increase in rsmA
expression in future studies. If algR was correctly being induced in the β-galactosidase assay
and Western blots, it is also possible that algR expression did not have an effect on rsmA in our
strains. Overexpression of algR was unable to restore alginate production, an AlgR dependent
phenotype (18). In addition, overexpression of algR has a deleterious effect on virulence (37).
This suggests AlgR levels are tightly maintained in the cell and that large alterations in AlgR
homoestasis are not favorable to P. aeruginosa. Intile, et al were able to see an increase in rsmA
expression, but this occurs in PA103, a different strain than the wild-type used for this study
(32). Additionally, the complementation construct used by Intile, et al. used both algZ and algR,
which may suggest a role for AlgZ in controlling rsmA. In addition, the expression vector used
in their study was plasmid based, compared to the chromosomal insertion used here. Overall, the
algR expression in this study did not affect rsmA transcription or protein levels in a significant
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manner, indicating that although mucA22ΔalgR possessed a noticeable RsmA defect, further
investigation must occur to implicate AlgR as the only reason for this decrease.
The second aim of this study was to define a mechanism for AlgR control of rsmA by
testing purified AlgR’s ability to bind the rsmA promoter. A purified fraction containing AlgR
was used in an EMSA on a labeled section of the rsmA probe containing the possible AlgR
binding site. The purified extract contained proteins not corresponding in size to AlgR, and thus
it was determined that stringent controls should be performed before using the extract in a gel
shift with rsmA. In a previous study, AlgR was shown not to bind to pscE/F (52). In this study,
the AlgR containing extract did not bind a pscE/F probe at 100 nM (Figure 14), indicating that
non-specific binding of the extract was not occurring. In the future, the AlgR concentration used
in the pscE/F binding reaction should match that used in the reactions with rsmA. The AlgR
containing extract (100 nM) was also able to shift a section of the algD promoter previously
shown to be bound by AlgR (44). Since the extract bound in a manner expected from AlgR, gel
shifts were also performed on the rsmA promoter. Purified extract was titrated in a binding
reaction with the rsmA probe, and was shown to bind rsmA and completely shift the probe
(Figure 15). The results of these gel shifts show that the purified extract binds positive and
negative probes in a manner expected by AlgR, and that binding is occurring to the rsmA probe
at 200 nM. Further studies can identify the exact concentration of AlgR required for binding, as
well as the sequence bound by AlgR. In addition, AlgR antibody could be used in the rsmA
binding reaction to illustrate a super-shift, indicating the rsmA shift seen in this study was due to
AlgR, and not another protein present in the extract. PAGE-purification of AlgR in the future
would mean the concentration of protein used in the binding reaction reflects the concentration
of AlgR by eliminating the possibility of erroneous quantification from non-AlgR proteins
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present in the purified lysate. Thrombin cleavage of the AlgR-GST fusion was completed for
12-16 hours, and lowering this treatment time may help lower the amount of background protein
present in the purified eluate. In addition, stringent control of probe concentration using dot-blot
analysis and a more specific titration by AlgR would yield more accurate results regarding
binding concentration. To show the in vivo relevance of AlgR binding rsmA within the cell, sitedirected mutagenesis was attempted at the AlgR binding site on the rsmA-lacZ transcriptional
fusion and remains incomplete. Creating the mutagenized construct and performing βgalactosidase assays may show that an intact AlgR binding site is required for rsmA expression
in the cell.
Intile, et al proposed that AlgR recalibrates rsmA expression to inhibit Type III Secretion,
a known RsmA regulatory target (32). The data presented in this study show that rsmA
expression in a mucA22 mutant is defective without AlgR, and a mechanism may exist whereby
AlgR directly binds and regulates the rsmA promoter. A concurrent study by this lab implicates
AlgU in control of rsmA expression (62). A model representing AlgU and AlgR control of rsmA
is depicted in Figure 16.
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Figure 16: AlgU and AlgR control of rsmA expression in the mucoid background.
Prior to the studies by this lab, transcriptional regulation of rsmA in P. aeruginosa was
unclear. Our findings suggest P. aeruginosa uses members of the alginate regulatory system to
tune virulence factor gene expression, which may help the cell transition from acute to chronic
infection. Future studies will attempt to elaborate upon the virulence implications of this
interaction. RsmA has been shown to repress Type VI Secretion (6), another secretion system
involved in P. aeruginosa virulence (46). Control of Type VI components was investigated as a
downstream readout for AlgR control of rsmA (Appendix F), but further studies are needed to
test the potential of this phenotype’s relevance to AlgU/AlgR control of rsmA.
Continued understanding of the complex regulatory hierarchies involved in regulation of
virulence factors by P. aeruginosa may identify crucial signals that push the cell towards the
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debilitating chronic infection, and could potentially identify drug targets. In the absence of gene
therapy treating cystic fibrosis, a treatment aimed at eliminating P. aeruginosa infection will
have significant impact on the prognosis for CF patients.
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APPENDICES
Appendix A: Media

Pseudomonas Isolation Agar (PIA):
In 2 L flask w/ stir bar:
940 ml ddH20
20 ml glycerol
25 mg Irgisan
20 g peptone
10 g K2SO4
1.4 g MgCl2 hexahydrate
13.6 g agar
Mix and boil solution. Autoclave. Add antibiotics when warm to touch.
Antibiotics and Supplemental concentrations:
150 ug/ml gentamicin
80 ug/ml X-gal
Arabinose to 1% (replace 25 mL H20 with 25 mL of 20% arabinose stock)
Luria-Bertani (LB) Media:
In 2 L flask w/ stir bar:
950 ml ddH2O
15g agar (if making plates)
10g NaCl
5g yeast extract
10g tryptone
Mix and autoclave. Add antibiotics when warm to touch.
Antibiotics and Supplemental concentrations:
15 μg/ml gentamicin
10 μg/ml tetracycline
100 μg/ml ampicillin
50 μg/ml kanamycin
1500 ug/ml trimethoprim
Arabinose to 1% (replace 25 mL H20 with 25 mL of 20% arabinose stock)
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LB no salt tet50 irg25 :
950 ml ddH2O
15g agar
5g yeast extract
10g tryptone
25 mg Irgasan
Mix and boil, then autoclave. Add 50 mg tetracycline when flask becomes warm to touch.

Vogel-Bonner Minimal Media (VBMM):
10X VBMM stock (500 ml):
400 ml ddH2O
15g trisodium citrate
10g citric acid
50g K2HPO4
17.5g NaNH4PO4 x 6 H20
Adjust pH to 7 and autoclave
1X VBMM:
400 ml ddH2O
7.5g Agar
autoclave and allow to cool to 50°C, then add:
50 ml 10X VBMM
500 μl 1M magnesium sulfate
50 μl 1M CaCl2
For VBMM + Carb => When flask is warm to touch, add 300 ug/ml carbenicillin

SOC Outgrowth Media:
2% Peptone
0.5% Yeast
10 mM NaCl
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4
20 mM Glucose
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Appendix B: Buffers and Solutions
10X TBE
108g Tris base
55g boric acid
Dissolve into 900 ml ddH2O and add 40 ml 0.5M EDTA (pH 8.0) and autoclave.
10X TE
100 ml 1M Tris-HCl (pH 7.5)
20 ml 0.5M EDTA (pH 8.0)
880 ml ddH2O and autoclave
Z-buffer
16.1g Na2HPO4 x 7 H2O
5.5g NaH2PO4 x 7 H2O
0.75g KCl
0.246g MgSO4 x 7 H2O
Add 900 ml ddH2O, adjust pH to 7 and autoclave
BME – Before assay, add 2.7 ul beta-mercaptoethanol / 1 ml Z buffer
ONPG – Just prior to assay, add 4 mg ONPG / 1 mL Z buffer and vortex until fully dissolved
1.5M Tris-HCl (pH 8.8)
27.23 g Tris base
80 ml ddH2O
Adjust pH to 8.8 w/ conc. HCl
ddH2O to 150 ml and autoclave
0.5M Tris-HCl (pH 6.8)
6.1 g Tris base
80 ml H2O
Adjust pH to 6.8 w/ conc. HCl
ddH2O to 100 ml and autoclave
10X Glycine Running Buffer
30.3 g Tris base
144.1 g glycine
10 g SDS
ddH2O to 1 L and mix on stir plate
10X Towbin Buffer
30.3 g Tris base
144 g glycine
ddH2O to 1 L and mix on stir plate
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SDS-PAGE Transfer Buffer
10 ml 10X Towbin buffer
20 ml methanol
70 ml ddH2O
10X Tris-buffered Saline
60.6 g Tris base
87.6 g NaCl
800 ml ddH2O
Adjust pH to 7.6 w/ 1M HCl
Add ddH2O to 1 L and autoclave
TBS-T:
Just before use, add 0.1% Tween-20 to 1X TBS
Western Blot Blocking Buffer
5 ml TBS-T
2.5 g Skim milk powder
ddH2O to 50 ml
Western Blot Washing Buffer
5 ml TBS-T
45 ml ddH2O
1˚ Antibody Solution
5 ml TBS-T
2.5 g Skim milk powder
ddH2O to 50 ml
Thaw antibody on ice and add based on desired dilution (2.5 ul for 1:20,000)
2˚ Antibody Solution
5 ml TBS-T
2.5 g Skim milk powder
ddH2O to 50 ml
Add anti-rabbit or anti-mouse based on desired dilution
Protein lysis buffer
10 ml 10X PBS (pH 7.4)
90 ml sddH2O
Just before use add:
Lysozyme to desired concentration
5 mM DTT
PMSF or other protease inhibitor
Place on ice until use
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10X Phosphate-buffered Saline (PBS)
80 g NaCl
2 g KCl
14.4 Na2HPO4
2.4 KH2HPO4
Dissolve in 800 ml ddH2O and adjust pH to 7.4
Add ddH2O to 1 L and autoclave
4X SDS-PAGE loading buffer
2.2 ml 0.5M Tris HCl (pH 6.8)
2.2 ml glycerol
1.1 ml 20% SDS
250 ul 1% Bromophenol blue
250 ul β-mercaptoethanol
Aliquot 1 ml into tubes and store at -20˚C
5X EMSA Binding Buffer
For 10 ml:
0.5 ml 1M Tris HCl (pH 8.0)
3 ml 2.5M KCl
50 ul 0.5M EDTA (pH 8.0)
50 ul Triton X-100
6.5 ml glycerol
Add 1 mM DTT just prior to use
6X EMSA loading dye “Blue Juice”
25 mg Bromophenol blue
4 g sucrose
ddH2O to 10 ml and filter sterilize
Aliquot 1 ml into tubes and store at -20˚C
4X Protein Storage Buffer
For 100 ml:
35 ml ddH2O
2.4 g Tris base
2.98 g KCl
30 ml glycerol
Adjust pH to 7.4 and add ddH2O to 100 ml
Filter sterilize and store at 4˚C
10x TNE
12.11 g Tris base
3.72 g EDTA
116.89 g NaCl
Dissolve above into 800 ml ddH2O, pH to 7.4 w. HCl and fill to 1 L then autoclave.
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Coomassie Staining Solution
For 100 mL 0.1% Solution:
Dissolve 0.1 g Coomassie Brilliant Blue into 100 mL containing the following:
50 ml Methanol
40 ml H2O
10 ml Glacial acetic acid
Coomassie Destaining Solution:
For 1 L, combine:
500 ml ddH2O
400 ml Methanol
100 ml Glacial acetic acid
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Appendix C: Strains, Primers and Plasmids
Table 6: Strains used in the study
Strain

Description

Source

PAO1

Wild-type acute strain

Lab Stock

mucA22

Wild-type chronic strain

Lab Stock

PAO1ΔalgR

algR mutant

This study

ΔalgRrsmAlacZ

ΔalgR; rsmAlacZ in attB
site

This study

mucA22rsmAlacZ

mucA22; rsmAlacZ in
attB site
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PAO1rsmAlacZ

rsmAlacZ in attB site

62

mucA22ΔalgRrsmAlacZ

mucA22&ΔalgR;
rsmAlacZ in attB site

This study

PAO1RsmA-HA

HA by allelic exchange

62

mucA22RsmA-HA

HA by allelic exchange

62

ΔalgRRsmA-HA

HA by allelic exchange

This study

mucA22ΔalgRRsmA-HA

HA by allelic exchange

This study

E. coli SM10

Sex pilus donor

Lab strain

E. coli BL21 (DE3)

Protein expression cells

New England
Biolabs
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Table 7: Primers and oligos used in study
Primer
pHERDSF

Sequence
ATCGCAACTCTCTACTGTTTCTC

pTJ1R

GTTTGGAACTAGATTTCACTTATCT

rsmASDMFcheck

GCCAAGGTTTCCATCGTCGG

rsmAGSR1

CACGCGAATATTTCAGGACAAC

lacZRforTF

CATCTGCTGCAAGGCGATTAAG

AlgRintF

GCAACTGGACTGGCAGGTGC

AlgRBXba1R

GCGCTCTAGAGCTCCAGCAGGTCCTCGGCC

pscFRBSF

GCTGGCGGAGTGTCGCCGGGAACTGGCCAGAGG

pscFRBSR

CCTCTGGCCAGTTCCCGGCGACACTCCGCCAGC

algDGS2F

CTTTCAGCCGCCATGCATTC

algDGS2R

GATGTTTTCTCTGCGAGGGAAG

Table 8: Plasmids used in study
Plasmid name

Description

Source

pTJ1algR

16

pGEX4T-2

algR expression vector,
tmpr
GST-fusion vector, ampr

pGEX4T-2algR

algR in pGEX4T-2, ampr

This study

pRK2013

Tra+, Mob+, kmr

Lab strain

pTNS3

Tra+, ampr

Lab strain

GE Healthcare
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Appendix D: Electrophoresis Gel Recipes
Table 9:1% Agarose gel recipe

Table 10: SDS-PAGE recipe
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Table 11: 6% TBE polyacrylamide gel recipe
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Appendix E: PCR and Restriction Digest Confirms pGEXalgR Transformation

Figure 17: Restriction digest and colony PCR confirm transformed BL21 has the algR
expression vector.
BL21 cells transformed with pGEXalgR were confirmed using restriction digest and
colony PCR to show they possessed the overexpression construct. Sal1-HF and Not1-HF were
used to drop out a ~750 bp fragment corresponding to the size of the cloned algR gene. PCR
amplified a similar sized fragment using the purified plasmid prep generated previously in the
lab as a positive control. Colony PCR of a single colony transformant generated a band of
similar size, indicating expression cells had been successfully transformed with pGEXalgR.
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Appendix F: AlgR and Type VI Secretion
During the course of this study it became apparent that AlgR control of rsmA may be
relevant to pathogenesis, since both algR and rsmA mutants are attenuated and each protein
control a wide variety of virulence factors. A virulence associated phenotype was pursued as a
readout for AlgR control of rsmA. P. aeruginosa uses the Type VI Secretion apparatus to
counterattack antagonizing bacteria (31, 46). Although the P. aeruginosa Type VI has not been
shown to attack eukaryotic cells, antibodies to Type VI components have been found in CF
patient serum (31). Since RsmA negatively regulates Type VI Secretion (6), it was hypothesized
that AlgR may modulate Type VI expression through RsmA. Antibody to HcP, a Type VI
component, was obtained in order to use Western Blotting as a means to analyze Type VI
expression in different mutant strains.

Figure 18: Differential expression of hcp occurs in various backgrounds. Cultures were grown
in LB broth for 5 hours and 10 ug protein / lane was loaded onto a 15% SDS-PAGE and treated
with antibody to either HcP (1:1000) or OMLA (1:20,000).
The strains shown in Figure 16 were chosen to establish a preliminary reason for further
investigation.
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In the non-mucoid strains, no discernible difference is seen in HcP between wild-type and
mutant strains. In the mucoid strains, HcP drops sharply. RsmA, algR and algU mutants show
differential expression of Type VI. The algR and algU mutants show higher protein levels
suggesting AlgR and AlgU are negative regulators of Type VI. The puzzling result was the
decrease in HcP in the rsmA mutant. As RsmA is a negative regulator of Type VI, it would be
expected that this mutant would have high levels of HcP. Further studies are needed to confirm
these results and Type VI activity in different strains.
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